Impact of streptozotocin-induced diabetes on functional responses of dendritic cells and macrophages towards Burkholderia pseudomallei

FEMS Immunology and Medical Microbiology

Volumn 61, Issue 2, 2011, Pages 218-227

  Williams, Natasha L ^a   Morris, Jodie L ^a   Rush, Catherine ^a   Govan, Brenda L ^a   Ketheesan, Natkunam ^a  

^a JAMES COOK UNIVERSITY   (Australia)

Author keywords

Burkholderia pseudomallei; C57BL 6; Dendritic cell; Diabetes; Macrophage; Melioidosis

Indexed keywords

CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; BONE MARROW; BURKHOLDERIA PSEUDOMALLEI; C57BL 6 MOUSE; CELL SURVIVAL; CHRONIC DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE PREDISPOSITION; EMERGENCY TREATMENT; GENE EXPRESSION PROFILING; HYPERGLYCEMIA; INTERNALIZATION; MACROPHAGE; MACROPHAGE FUNCTION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; STREPTOZOCIN DIABETES;

ANIMALS; BURKHOLDERIA PSEUDOMALLEI; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; DIABETES MELLITUS; GENE EXPRESSION PROFILING; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; MICROBIAL VIABILITY; STREPTOZOCIN;

EID: 79951508487     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2010.00767.x     Document Type: Article

References (32)

1. Barnes JL & Ketheesan N (2005) Route of infection in Melioidosis. Emerg Infect Dis 11: 638-639.
2. Barnes JL & Ketheesan N (2007) Development of protective immunity in a murine model of melioidosis is influenced by the source of Burkholderia pseudomallei antigens. Immunol Cell Biol 85: 551-557.
3. Barnes JL, Williams NL & Ketheesan N (2008) Susceptibility to Burkholderia pseudomallei is associated with host immune responses involving tumor necrosis factor receptor-1 (TNFR1) and TNF receptor-2 (TNFR2). FEMS Immunol Med Mic 52: 379-388.
4. Chanchamroen S, Kewcharoenwong C, Susaengrat W, Ato M & Lertmemongkolchai G (2009) Human polymorphonuclear neutrophil responses to Burkholderia pseudomallei in healthy and diabetic subjects. Infect Immun 77: 456-463.
5. Charoensap J, Engering A, Utaisincharoen P, van Kooyk Y & Sirisinha S (2008) Activation of human monocyte-derived dendritic cells by Burkholderia pseudomallei does not require binding to the C-type lectin DC-SIGN. T Roy Soc Trop Med H 102 (suppl 1): S76-S81.
6. Charoensap J, Utaisincharoen P, Engering A & Sirisinha S (2009) Differential intracellular fate of Burkholderia pseudomallei 844 and Burkholderia thailandensis UE5 in human monocyte-derived dendritic cells and macrophage. BMC Immunol 10: 20.
7. Cheng AC & Currie BJ (2005) Melioidosis: epidemiology, pathophysiology and management. Clin Microbiol Rev 18: 383-416.
8. Currie BJ, Fisher DA, Howard DM et al. (2000) Endemic melioidosis in tropical northern Australia: a 10-year study and review of the literature. Clin Infect Dis 31: 981-986.
9. de Jong EC, Smits H & Kapsenberg ML (2005) Dendritic cell-mediated T cell polarization. Springer Semin Immun 26: 289-307.
10. Easton A, Haque A, Chu K, Lukaszewski R & Bancroft G (2007) A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. J Infect Dis 195: 99-107.
11. Ekchariyawat P, Pudla S, Limposuwan K, Arjcharoen S, Srisinha S & Utaisincharoen P (2005) Burkholderia pseudomallei-induced expression of suppressor of cytokine signaling 3 and cytokine-inducible src homology 2-containing protein in mouse macrophages: a possible mechanism for suppression of the response to gamma interferon stimulation. Infect Immun 73: 7332-7339.
12. Elvin SJ, Healey GD, Westwood A, Knight SC, Eyles JE & Williamson ED (2006) Protection against heterologous Burkholderia pseudomallei strains by dendritic cell immunization. Infect Immun 74: 1706-1711.
13. Feterl M, Govan BL & Ketheesan N (2008) The effect of different Burkholderia pseudomallei isolates of varying levels of virulence on toll-like-receptor expression. T Roy Soc Trop Med H 102 (suppl 1): S82-S88.
14. Healey GD, Elvin SJ, Morton M & Williamson ED (2006) Humoral and cell mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance postinfection. Infect Immun 73: 5945-5951.
15. Kandasamy Y & Norton R (2008) Paediatric melioidosis in North Queensland, Australia. J Paediatr Child H 44: 706-708.
16. Koo GC & Gan Y-H (2006) The innate interferon gamma response of BALB/c and C57BL/6 mice to in vitro Burkholderia pseudomallei infection. BMC Immunol 7: 19-31.
17. Leakey AK, Ulett GC & Hirst RG (1998) BALB/c and C57BL/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis. Microb Pathogenesis 24: 269-275.
18. Lu W-T, Juang J-H, Hsu BR & Huang H-S (1998) Effects of high or low dose of streptozotocin on pancreatic islets in C57BL/6 and C.B17-SCID mice. Transplant P 30: 609-610.
19. Lutz MB, Kukutsch N, Ogilvie ALJ, Robner S, Koch F, Romani N & Schuler G (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223: 77-92.
20. Ma H, Liu G, Ding W, Wu Y, Cai L & Zhao Y (2008) Diabetes-induced F4/80+ macrophages: a study in mice with streptozotocin-induced diabetes for a chronic. J Mol Med 86: 391-400.
21. Malczewskie AB, Oman KM, Norton RE & Ketheesan K (2005) Clinical presentation of melioidosis in Queensland, Australia. T Roy Soc Trop Med H 99: 856-860.
22. Marhoffer W, Stein M, Maeser E & Federlin K (1992) Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 15: 256-260.
23. O'Connor JC, Sherry CL, Guest CB & Freund CG (2007) Type 2 diabetes impairs insulin receptor substrate-2-mediated phosphatidlyinositol 3-kinase activity in primary macrophages to induce a state of cytokine resistance to IL-4 in association with overexpression of suppressor of cytokine signaling-3. J Immunol 178: 6886-6893.
24. Pradhan AD, Manson JE, Rifai N, Buring JE & Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J Am Med Assoc 286: 327-334.
25. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H & Pfeiffer AF (2003) Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52: 812-817.
26. Srinivasan K & Ramarao P (2007) Animal models in type 2 diabetes research: an overview. Indian J Med Res 125: 451-472.
27. Suputtamongkol Y, Chaowagul W, Chetchotisakd P et al. (1999) Risk factors for melioidosis and bacteremic melioidosis. Clin Infect Dis 29: 408-413.
28. Szkudelzki T (2001) The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50: 536-546.
29. Ueki K, Kondo T & Kahn CR (2004) Suppressor of cytokine signaling-1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24: 5434-5446.
30. Ulett GC, Ketheesan N & Hirst RG (2000) Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei. Infect Immun 68: 2034-2042.
31. Utaisincharoen P, Tangthawornchaikul N, Kespichayawattana W, Chaisuriya P & Sirisinha S (2001) Burkholderia pseudomallei interferes with inducible nitric oxide synthase (iNOS) production: a possible mechanism of evading macrophage killing. Microbiol Immunol 45: 307-313.
32. Williams NL, Kloeze E, Govan BL, Körner H & Ketheesan N (2008) Burkholderia pseudomallei enhances maturation of bone marrow derived dendritic cells. T Roy Soc Trop Med H 102 (suppl 1): S71-S75.